As of September 30, 2024, the Company had cash of approximately $7.0 million. Subsequent to the quarter end, the Company closed a $3.0 million registered direct offering of common stock priced at the market under Nasdaq rules, as well as completing $1.6 million of offerings via the Company’s at-the-market facility. Based on management’s planned activities and current expectations, cash on hand is sufficient to fund our operations through the second quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CNSP:
- CNS Pharmaceuticals: Financial Results and Strategic Moves
- CNS Pharmaceuticals granted exception by Nasdaq to regain compliance
- Biotech Alert: Searches spiking for these stocks today
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
